LB Pharmaceuticals (LBRX) Competitors $15.52 -0.55 (-3.42%) As of 03:39 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock LBRX vs. SNDX, EVO, AVDL, ZYME, TSHA, ORIC, SION, XERS, NUVB, and AMLXShould you be buying LB Pharmaceuticals stock or one of its competitors? The main competitors of LB Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Evotec (EVO), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Taysha Gene Therapies (TSHA), Oric Pharmaceuticals (ORIC), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Nuvation Bio (NUVB), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. LB Pharmaceuticals vs. Its Competitors Syndax Pharmaceuticals Evotec Avadel Pharmaceuticals Zymeworks Taysha Gene Therapies Oric Pharmaceuticals Sionna Therapeutics Xeris Biopharma Nuvation Bio Amylyx Pharmaceuticals Syndax Pharmaceuticals (NASDAQ:SNDX) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Does the media refer more to SNDX or LBRX? In the previous week, LB Pharmaceuticals had 12 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 16 mentions for LB Pharmaceuticals and 4 mentions for Syndax Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 1.05 beat Syndax Pharmaceuticals' score of 0.77 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SNDX or LBRX? Syndax Pharmaceuticals currently has a consensus price target of $39.22, suggesting a potential upside of 156.27%. LB Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 96.52%. Given Syndax Pharmaceuticals' higher probable upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than LB Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82LB Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SNDX or LBRX more profitable? LB Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -428.48%. LB Pharmaceuticals' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax Pharmaceuticals-428.48% -130.47% -56.12% LB Pharmaceuticals N/A N/A N/A Which has better earnings & valuation, SNDX or LBRX? LB Pharmaceuticals has lower revenue, but higher earnings than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M55.67-$318.76M-$3.89-3.93LB PharmaceuticalsN/AN/AN/AN/AN/A SummaryLB Pharmaceuticals beats Syndax Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get LB Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LBRX vs. The Competition Export to ExcelMetricLB Pharmaceuticals IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$348.27M$2.47B$2.51B$10.51BDividend YieldN/A13.90%2.53%4.82%P/E RatioN/A28.3526.1727.36Price / SalesN/A6,125.27128.30135.63Price / CashN/A20.7445.0330.18Price / BookN/A3.3137.636.79Net IncomeN/A-$331.88M$6.97M$276.59M7 Day Performance-3.06%-0.36%-0.80%1.08%1 Month PerformanceN/A1.51%0.97%8.50%1 Year PerformanceN/A13.41%59.48%44.54% LB Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LBRXLB PharmaceuticalsN/A$15.52-3.4%$30.50+96.5%N/A$348.27MN/A0.0016News CoveragePositive NewsSNDXSyndax Pharmaceuticals3.6382 of 5 stars$16.06-0.9%$39.22+144.2%-20.5%$1.38B$77.93M-4.13110EVOEvotec2.1525 of 5 stars$3.87-1.8%$7.00+80.9%+25.8%$1.37B$862.40M0.004,827Gap DownAVDLAvadel Pharmaceuticals2.6921 of 5 stars$14.00-1.4%$20.86+49.0%+8.2%$1.36B$169.12M-466.6770News CoverageZYMEZymeworks2.3072 of 5 stars$18.06+6.7%$22.50+24.6%+37.2%$1.36B$122.87M-12.04460News CoverageAnalyst ForecastGap UpHigh Trading VolumeTSHATaysha Gene Therapies2.3857 of 5 stars$4.88-2.4%$9.00+84.4%+151.2%$1.33B$8.33M-14.35180ORICOric Pharmaceuticals4.2557 of 5 stars$13.68-2.8%$17.29+26.4%+49.1%$1.33BN/A-7.2480Gap UpSIONSionna Therapeutics2.7004 of 5 stars$29.42+3.8%$38.00+29.2%N/A$1.30BN/A0.0035XERSXeris Biopharma2.7741 of 5 stars$7.99-2.4%$7.08-11.3%+173.2%$1.29B$246.03M-38.05290NUVBNuvation Bio2.8125 of 5 stars$3.73-0.5%$7.86+110.6%+62.3%$1.28B$7.87M-5.9260Analyst ForecastAMLXAmylyx Pharmaceuticals1.8173 of 5 stars$14.26-1.5%$14.75+3.4%+297.7%$1.27B$87.37M-5.70200 Related Companies and Tools Related Companies Syndax Pharmaceuticals Alternatives Evotec Alternatives Avadel Pharmaceuticals Alternatives Zymeworks Alternatives Taysha Gene Therapies Alternatives Oric Pharmaceuticals Alternatives Sionna Therapeutics Alternatives Xeris Biopharma Alternatives Nuvation Bio Alternatives Amylyx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LBRX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LB Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share LB Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
